Firinu D, Barca MP, Serusi L, Lorrai MM, Peralta MM, Manconi PE, Del Giacco SR. Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report.
Int J Immunopathol Pharmacol 2012;
25:269-73. [PMID:
22507340 DOI:
10.1177/039463201202500130]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Icatibant, an antagonist of the bradykinin B2 receptor, was approved for the treatment of acute attacks of hereditary angioedema in the EU in 2008. This paper presents the case of a 65-year-old woman affected by frequent acute attacks of hereditary angioedema who benefitted from a change of therapy to icatibant, following years of treatment with C1-inhibitor.
Collapse